Efficacy of combinations of BRAF inhibitors and anti-EGFR antibodies in metastatic colorectal carcinoma (mCRC) patients with mBRAF in the real clinical practice

被引：0

作者：

Fedyanin, M. ^{[1
]}

Elsnukaeva, H. ^{[1
]}

Demidova, I. ^{[2
]}

Stroyakovskiy, D. ^{[3
]}

Shelygin, Y. ^{[4
]}

Tsukanov, A. ^{[5
]}

Panina, M. ^{[6
]}

Moiseenko, F. ^{[7
]}

Karpenko, E. ^{[8
]}

Bolotina, L. ^{[8
]}

Kudryavtseva, A. ^{[9
]}

Filipenko, M. ^{[10
]}

Oskorbin, I. ^{[10
]}

Vladimirova, L. Y. ^{[11
]}

Timoshkina, N. N. ^{[12
]}

Kit, O. I. ^{[13
]}

Stroganova, A. ^{[14
]}

Dranko, S. ^{[14
]}

Tryakin, A. ^{[1
]}

Tjulandin, S. ^{[1
]}

机构：

[1] Minist Hlth Russian Federat NN Blokhin NMRCO, NN Blokhin Natl Med Res Ctr Oncol, Fed State Budgetary Inst, Clin Pharmacol & Chemotherapy, Moscow, Russia

[2] Moscow City Oncol Hosp 62, Moscow Dept Hlth, Genet, Moscow, Russia

[3] Moscow City Oncol Hosp 62, Moscow Dept Hlth, Chemotherapy, Moscow, Russia

[4] Minister Hlth, State Sci Ctr Coloproctol, Moscow, Russia

[5] Minister Hlth, State Sci Ctr Coloproctol, Genet, Moscow, Russia

[6] Minister Hlth, State Sci Ctr Coloproctol, Oncol Dept, Moscow, Russia

[7] St Petersburg Clin Res & Pract Ctr Specialized Ty, Oncol, St Petersburg, Russia

[8] Minist Hlth Russian Federat RF, Branch Natl Med Res Radiol Ctr, RA Hertsen Moscow Oncol Res Inst, Chemotherapy, Moscow, Russia

[9] Russian Acad Sci, EIMB Engelhardt Inst Mol Biol, Lab Postgen Studies, Moscow, Russia

[10] Inst Clin Biol & Fundamental Med, Genet, Novosibirsk, Russia

[11] Natl Med Res Ctr Oncol, Med Oncol Dept, Rostov Na Donu, Russia

[12] Natl Med Res Ctr Oncol, Lab Mol Oncol, Rostov Na Donu, Russia

[13] Natl Med Res Ctr Oncol, Rostov Na Donu, Russia

[14] Minist Hlth Russian Federat NN Blokhin NMRCO, NN Blokhin Natl Med Res Ctr Oncol, Fed State Budgetary Inst, Genet, Moscow, Russia

来源：

ANNALS OF ONCOLOGY | 2021年 / 32卷

关键词：

D O I：

10.1016/j.annonc.2021.08.969

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

448P

引用

页码：S557 / S558

页数：2

共 50 条

[31] Beyond KRAS: Predictive factors of the efficacy of anti-EGFR monoclonal antibodies in the treatment of metastatic colorectal cancer
De Stefano, Alfonso
Carlomagno, Chiara
WORLD JOURNAL OF GASTROENTEROLOGY, 2014, 20 (29) : 9732 - 9743
[32] Cetuximab rechallenge in RAS, BRAF, EGFR-ECD wild type metastatic colorectal cancer (mCRC) patients treated with anti-EGFR therapies in first line: The CITRIC study
Santos Vivas, C.
Salva, F.
Fernandez-Rodriguez, C.
Alonso Orduna, V.
Losa, F.
Paez, D.
Vidal, J.
Salud, A.
Ribera Fernandez, P.
Safont Aguilera, M.
Tarazona, N.
Hernandez-Yague, X.
Layos Romero, L.
Garcia-Carbonero, R.
Rivera, F.
Alvarez Gallego, R.
Bellosillo, B.
Montagut, C.
ANNALS OF ONCOLOGY, 2022, 33 : S291 - S291
[33] BRAF mutation predicts resistance to anti-EGFR monoclonal antibodies in wild-type KRAS metastatic colorectal cancer
Chen Mao
Ru-Yan Liao
Qing Chen
Journal of Cancer Research and Clinical Oncology, 2010, 136 : 1293 - 1294
[34] BRAF mutation predicts resistance to anti-EGFR monoclonal antibodies in wild-type KRAS metastatic colorectal cancer
Mao, Chen
Liao, Ru-Yan
Chen, Qing
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2010, 136 (08) : 1293 - 1294
[35] The Prognostic Role of BRAF Mutation in Metastatic Colorectal Cancer Receiving Anti-EGFR Monoclonal Antibodies: A Meta-Analysis
Yuan, Zi-Xu
Wang, Xiao-Yan
Qin, Qi-Yuan
Chen, De-Feng
Zhong, Qing-Hua
Wang, Lei
Wang, Jian-Ping
PLOS ONE, 2013, 8 (06):
[36] Retreatment With Anti-EGFR Antibodies in Metastatic Colorectal Cancer Patients: A Multi-institutional Analysis
Rossini, Daniele
Germani, Marco Maria
Pagani, Filippo
Pellino, Antonio
Dell'Aquila, Emanuela
Bensi, Maria
Liscia, Nicole
Moretto, Roberto
Boccaccino, Alessandra
Prisciandaro, Michele
Manglaviti, Sara
Schirripa, Marta
Vivolo, Raffaella
Scartozzi, Mario
Santini, Daniele
Salvatore, Lisa
Pietrantonio, Filippo
Loupakis, Fotios
Falcone, Alfredo
Cremolini, Chiara
CLINICAL COLORECTAL CANCER, 2020, 19 (03) : 191 - +
[37] Comprehensive analysis of egfr and its downstream pathways deregulation identifies the vast majority of metastatic colorectal cancer (mCRC) patients resistant to anti-egfr monoclonal antibodies (MoAbs)
Frattini, M.
Molinari, F.
De Dosso, S.
Martin, V
Crippa, S.
Saletti, P.
Mazzucchelli, L.
VIRCHOWS ARCHIV, 2009, 455 : 46 - 46
[38] Rational drug combinations to improve anti-EGFR targeted therapies in metastatic colorectal cancer
Bertotti, Andrea
CANCER RESEARCH, 2014, 74 (19)
[39] Rechallenge with anti-EGFR antibodies in metastatic colorectal cancer: A single center analysis
Duarte Mendes, A.
Vicente, R.
Caleca, T.
Silva, M.
ANNALS OF ONCOLOGY, 2023, 34 : S149 - S149
[40] Anti-EGFR monoclonal antibodies in metastatic colorectal cancer: time for an individualized approach?
Fakih, Marwan
EXPERT REVIEW OF ANTICANCER THERAPY, 2008, 8 (09) : 1471 - 1480

← 1 2 3 4 5 →